600557 Jiangsu Kanion Pharmaceutical
- 15.68
- -0.56-3.45%
Jiangsu Kanion Pharmaceutical News
Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) Market Cap Surged CN¥453m Last Week, Private Companies Who Have a Lot Riding on the Company Were Rewarded
Key Insights The considerable ownership by private companies in Jiangsu Kanion PharmaceuticalLtd indicates that they collectively have a greater say in management and business strategy The top 9
Jiangsu Kanion Pharmaceutical (600557.SH): Vice President Wu Yun resigns for personal reasons.
On July 18th, Gelunhui reported that Jiangsu Kanion Pharmaceutical (600557.SH) announced that the company's board of directors recently received a written resignation report submitted by Mr. Wu Yun, the company's deputy general manager. Due to personal reasons, Mr. Wu Yun applied to resign from his position as deputy general manager of the company. After resigning, Mr. Wu Yun will no longer hold any position in the company and its subsidiaries. As of the date of this announcement, Mr. Wu Yun holds 105,000 shares of the company's stocks, all of which are restricted stocks granted by the company's 2022 restricted stock incentive plan, with 60,000 shares still subject to restriction. The company will act in accordance with the 2022 Restricted Stock Plan to deal with restricted stocks.
Jiangsu Kanion Pharmaceutical (600557.SH): Has repurchased 0.966% of the shares.
On July 2, Glonhui reported that Jiangsu Kanion Pharmaceutical (600557.SH) announced that as of June 28, 2024, the company had repurchased a total of 5,619,989 shares, accounting for 0.9660% of the company's current total share capital. The highest price purchased was 19.98 yuan/share, the lowest was 15.62 yuan/share, and the total amount paid was 95,817,791.98 yuan (including transaction fees).
Jiangsu Kanion Pharmaceutical (600557.SH) director Chen Xuebin's relatives engaged in short-term trades and apologized.
Jiangsu Kanion Pharmaceutical (600557.SH) announced that Mr. Chen Xuebin, a director of the company, resigned due to the death of his spouse, Ms. Miao Jianbo, on 20...
Jiangsu Kanion PharmaceuticalLtd's (SHSE:600557) Three-year Total Shareholder Returns Outpace the Underlying Earnings Growth
It hasn't been the best quarter for Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) shareholders, since the share price has fallen 26% in that time. But don't let that distract from the very n
Jiangsu Kanion Pharmaceutical (600557.SH): has repurchased a total of 1.3137 million shares of stock.
On June 4th, Gelonghui announced that Jiangsu Kanion Pharmaceutical (600557.SH) has repurchased a total of 1,313,700 shares as of May 31, 2024, accounting for 0.2258% of the company's total share capital. The highest purchase price was 19.98 yuan/share and the lowest purchase price was 16.27 yuan/share. The total amount paid was 22,740,711.37 yuan (including transaction costs).
Does Jiangsu Kanion PharmaceuticalLtd (SHSE:600557) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Sometime
Kangyuan Pharmaceutical (600557.SH) will distribute the 2023 cash dividend of 0.37203 yuan per share on May 31
Kangyuan Pharmaceutical (600557.SH) announced that the company will release the 2023 fiscal year on May 31, 2024...
China Merchants Securities: The 24Q1 Chinese medicine sector has steadily overcome high base pressure, and profit levels and dividends have improved markedly
The traditional Chinese medicine industry was slightly under pressure due to high base pressure in the short term, but the level of profit and dividends performed well. In the context of policies encouraging the inheritance, innovation and development of traditional Chinese medicine, along with the reform of state-owned enterprises and the implementation of catalytic events such as the basic drug catalogue, the traditional Chinese medicine sector is still cost-effective.
Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Most readers would already be aware that Jiangsu Kanion PharmaceuticalLtd's (SHSE:600557) stock increased significantly by 15% over the past three months. We wonder if and what role the company's fi
Kangyuan Pharmaceutical (600557.SH): A total cost of 17.34 million yuan to buy back 0.1733% of shares
Gelonghui, May 7, 丨 Kangyuan Pharmaceutical (600557.SH) announced that as of April 30, 2024, the company had repurchased a total of 1,013,600 shares, accounting for 0.1733% of the company's total share capital. The highest purchase price was 19.83 yuan/share, the lowest price was 16.27 yuan/share, and the total amount paid was 17,344,891.23 yuan (including transaction fees).
Jiangsu Kanion PharmaceuticalLtd's (SHSE:600557) Earnings May Just Be The Starting Point
Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) earnings announcement last week was disappointing for investors, despite the decent profit numbers. We have done some analysis and have found so
Kangyuan Pharmaceutical (600557.SH): Net profit of 148 million yuan in the first quarter increased 4.67% year-on-year
Gelonghui, April 12 | Kangyuan Pharmaceutical (600557.SH) released its first quarter report. Operating revenue was 1,359 million yuan, up 0.48% year on year, net profit of 148 million yuan, up 4.67% year on year, after deducting non-net profit of 140 million yuan, up 0.20% year on year, with basic earnings per share of 0.26 yuan.
Is There An Opportunity With Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) 36% Undervaluation?
Key Insights The projected fair value for Jiangsu Kanion PharmaceuticalLtd is CN¥31.77 based on 2 Stage Free Cash Flow to Equity Current share price of CN¥20.20 suggests Jiangsu Kanion Pharmaceutica
Kangyuan Pharmaceutical (600557.SH): A total cost of 14.12 million yuan to buy back 0.15% of shares
Gelonghui, April 1, 丨 Kangyuan Pharmaceutical (600557.SH) announced that as of March 31, 2024, the company had repurchased a total of 849,300 shares, accounting for 0.15% of the company's total share capital. The highest transaction price purchased was 17.93 yuan/share, the lowest transaction price was 16.27 yuan/share, and the total amount paid was 14,121,888.36 yuan.
Kangyuan Pharmaceutical (600557.SH): Received an approval notice for clinical trials of injectable AAPB
Gelonghui, March 28, 丨 Kangyuan Pharmaceutical (600557.SH) announced that it has recently received the “Drug Clinical Trial Approval Notice” for Class 1 AAPB (two specifications) for injecting new chemical drugs issued by the State Drug Administration. Injectable AAPB is a novel anti-ischemic stroke neuroprotector jointly developed by the company and China Pharmaceutical University. The formulation specifications are 10 mg and 25 mg, and clinically intended for acute ischemic stroke.
Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) Yearly Results: Here's What Analysts Are Forecasting For This Year
Shareholders of Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) will be pleased this week, given that the stock price is up 14% to CN¥21.41 following its latest full-year results. Jiangsu K
Kangyuan Pharmaceutical (600557.SH)'s net profit in 2023 increased by 23.54% to $537 million, with a dividend of 0.37 yuan per share
Gelonghui, March 10 | Kangyuan Pharmaceutical (600557.SH) announced that in 2023, the company's annual business performance will steadily improve, breaking the game through reforms and constructing a new trend of high-quality development for the company. During the reporting period, the company's consolidated statements achieved operating income of 4.868 billion yuan, up 11.88% year on year, and net profit attributable to shareholders of listed companies of 537 million yuan, an increase of 23.54% year on year. The company plans to distribute a cash dividend of 0.37 yuan (tax included) per share to all shareholders, no bonus shares, and no capital increase from the capital reserve fund.
Kangyuan Pharmaceutical (600557.SH): A total of 849,300 shares have been repurchased
Gelonghui, March 1, 丨 Kangyuan Pharmaceutical (600557.SH) announced that as of February 29, 2024, the company had repurchased a total of 849,300 shares through the Shanghai Stock Exchange system, accounting for about 0.15% of the company's total share capital. The highest transaction price purchased was 17.93 yuan/share, the minimum transaction price was 16.27 yuan/share, and the average repurchase price was 16.63 yuan/share. The total amount paid was 14,121,888.36 yuan (including transaction fees).
Kangyuan Pharmaceutical (600557.SH): Initial repurchase of 611,300 shares
Gelonghui, February 7, 丨 Kangyuan Pharmaceutical (600557.SH) announced that on February 7, 2024, the company repurchased 611,300 shares of the company's shares for the first time through centralized bidding. The repurchased shares accounted for 0.10% of the company's total share capital. The highest transaction price purchased was 16.82 yuan/share, the minimum transaction price was 16.27 yuan/share, and the average repurchase price was 16.48 yuan/share. The total amount paid was 10,074,476.26 yuan (including transaction fees).
Analysis
Price Target
No Data
